Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744207 | 0.94 | IDO1 (0.53) | IDO1TDO2 | |
| SCHEMBL22188419 | 0.82 | IDO1 (0.53) | IDO1TDO2 | |
| SCHEMBL22188389 | 0.78 | IDO1 (0.51) | IDO1TDO2 | |
| SCHEMBL20744200 | 0.78 | IDO1 (0.51) | IDO1TDO2 | |
| SCHEMBL28442115 | 0.75 | IDO1 (0.59) | IDO1TDO2 | |
| SCHEMBL28888462 | 0.73 | IDO1 (0.56) | IDO1TDO2 | |
| SCHEMBL22683651 | 0.72 | IDO1 (0.38) | IDO1TDO2 | |
| SCHEMBL22683652 | 0.72 | IDO1 (0.38) | IDO1TDO2 | |
| SCHEMBL20743573 | 0.71 | IDO1 (0.41) | IDO1TDO2 | |
| SCHEMBL20743849 | 0.71 | IDO1 (0.43) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | IDO1 3/4885TDO2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.